AstraZeneca May Buy Bristol Myers Squibb in Giant Drug Deal

AstraZeneca is talking to US rival Bristol Myers Squibb about a possible takeover, the Financial Times reported on 3 August 2026, citing unnamed sources. Together the two drug companies would be worth nearly $400bn — making the world's fourth-largest by value. Talks may not succeed. AstraZeneca's share price dropped over 7% on the news.